Continuous Glucose Monitoring

Education for Managed Care, Pharmacy, and Payer Professionals


Expert Interview Series with Professor Thomas Danne

Expert: Thomas Danne, MD, Professor of Pediatrics, Children’s Hospital Auf der Bult, Hanover, Germany

Part 1 – Glycemic Control: Opportunities and Challenges

International Consensus on Use of Continuous Glucose Monitoring
Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range 

Part 2 – Time in Range and Reduction in Diabetes-Related Complications

Going Beyond A1c – One Outcome Can’t Do It All
Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials
Continuous Glucose Monitoring in Adults with Type 1 Diabetes: Real-World Data from the German/Austrian Prospective Diabetes Follow-Up Registry

Part 3 – Virtual Care and the Future of CGM

Acceptability and Utilization of Newer Technologies and Effects on Glycemic Control in Type 2 Diabetes: Lessons Learned from Lockdown
Blood Glucose Control During Lockdown for COVID-19: CGM Metrics in Italian Adults With Type 1 Diabetes
Personal Experience With COVID-19 and Diabetes in the South of France: Technology Facilitates the Management of Diabetes in Disruptive Times

Expert Interview

Appropriate Utilization Management Strategies for Continuous Glucose Monitoring

Expert: Jeffrey D. Dunn, PharmD, MBA, (Formerly) Vice President, Clinical Strategy and Programs and Industry Relations at Magellan Rx Management